A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of SCB-313 in patients with peritoneal
carcinomatosisa, to determine the maximum tolerated dose (MTD) and/or extended study
recommended dose (RDE) for SCB-313 intraperitoneal injection, providing a basis for dosing
regimen and dose choosing in clinical trial subsequently.